Jump to content

Trenbolone hexahydrobenzylcarbonate

From Wikipedia, the free encyclopedia
Trenbolone hexahydrobenzylcarbonate
Clinical data
Trade namesParabolan, Hexabolan
Other namesTrenbolone cyclohexylmethylcarbonate; Estra-4,9,11-trien-17β-ol-3-one 17β-cyclohexylmethylcarbonate
Routes of
administration
Intramuscular
Drug classAndrogen; Anabolic steroid; Androgen ester; Progestogen
Legal status
Legal status
Identifiers
  • Cyclohexylmethyl [(8S,13S,14S,17S)-13-methyl-3-oxo-2,6,7,8,14,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl] carbonate
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.041.503 Edit this at Wikidata
Chemical and physical data
FormulaC26H34O4
Molar mass410.554 g·mol−1
3D model (JSmol)
  • C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@H]2OC(=O)OCC5CCCCC5
  • InChI=1S/C26H34O4/c1-26-14-13-21-20-10-8-19(27)15-18(20)7-9-22(21)23(26)11-12-24(26)30-25(28)29-16-17-5-3-2-4-6-17/h13-15,17,22-24H,2-12,16H2,1H3/t22-,23+,24+,26+/m1/s1
  • Key:GQJSFWYQKNQCIK-APFRJGHOSA-N

Trenbolone hexahydrobenzylcarbonate, or trenbolone cyclohexylmethylcarbonate, sold under the brand names Parabolan and Hexabolan, is a synthetic, injected anabolic–androgenic steroid (AAS) of the nandrolone group and an androgen ester – specifically, the C17β hexahydrobenzylcarbonate (cyclohexylmethylcarbonate) ester of trenbolone – which was marketed in France for medical use in humans but has since been discontinued.[1]

It was marketed from 1971 to 1997 for cachexia, recovery from major surgery, burns and pressure ulcers, and certain forms of osteoporosis. The standard dose was one ampoule (76 mg of trenbolone hexahydrobenzylcarbonate, equivalent to 50 mg base trenbolone) per fifteen days for a month, then one ampoule per month for three months.[2][3] The drug acts as a long-lasting prodrug of trenbolone when administered via intramuscular injection.[1]

See also

[edit]

References

[edit]
  1. 1 2 William Llewellyn (2011). Anabolics. Molecular Nutrition Llc. pp. 619–. ISBN 978-0-9828280-1-4.
  2. ↑ "PARABOLAN solution injectable (arrêt de commercialisation)". BIAM – Banque de Données Automatisée sur les Médicaments (in French). Archived from the original on 7 June 2003.
  3. ↑ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia. Elsevier. pp. 3307–. ISBN 978-0-8155-1856-3.

Further reading

[edit]
  • Yarrow JF, McCoy SC, Borst SE (2010). "Tissue selectivity and potential clinical applications of trenbolone (17beta-hydroxyestra-4,9,11-trien-3-one): A potent anabolic steroid with reduced androgenic and estrogenic activity". Steroids. 75 (6): 377–89. doi:10.1016/j.steroids.2010.01.019. PMID 20138077. S2CID 205253265.
[edit]